- 01U.S. PARADIGM trial enrollment commenced, supported by CMS coverage.
- 02Significant capital raises in early 2026 strengthen balance sheet.
- 03High cash burn continues, posing ongoing financing risk.
Anteris Technologies Global (AVR.ASX) has initiated US patient enrolment in its pivotal PARADIGM trial and secured substantial funding, demonstrating operational progress.
Anteris reported net operating cash outflows of US$28.7 million for the first quarter of 2026, primarily driven by clinical, regulatory, and manufacturing requirements for the PARADIGM trial.
Despite the cash burn, the company significantly bolstered its liquidity with aggregate capital raises totalling US$320 million in January 2026.
These financings included a public offering that raised approximately US$230.0 million and a private placement with Medtronic for approximately US$90.0 million.
Consequently, cash and restricted cash sharply increased to US$283.2 million at March 31, 2026, up from US$12.6 million at the end of December 2025.
Total stockholders' equity also improved to US$278.4 million from a previous deficit.
PARADIGM Trial US Enrolment
Post quarter-end, Anteris commenced U.S. patient enrolment in its global pivotal PARADIGM trial for the DurAVR Transcatheter Heart Valve (THV) system.
This significant step followed the securing of US Medicare reimbursement eligibility under CMS's Transcatheter Aortic Valve Replacement (TAVR) National Coverage Determination 20.32.
The CMS coverage determination is expected to facilitate US patient recruitment by supporting reimbursement and site-level adoption.
The PARADIGM trial is a prospective, randomised controlled study targeting 1,000 patients with a 1:1 randomisation ratio, comparing DurAVR against commercially available TAVRs.
Operational and Manufacturing Milestones
Beyond trial enrolment, Anteris has continued to strengthen its operational infrastructure.
This includes advancing its quality management and manufacturing scale-up, achieving ISO 13485 certification for DurAVR THV production.
Clinical data from the EMBARK Study and the U.S. Early Feasibility Study were presented at CRT 2026 and Sydney Valves 2026.
These presentations detailed favourable short-term clinical outcomes from early cohorts of patients treated with DurAVR THV.
Financial Performance and Expenses
For the quarter ended March 31, 2026, Anteris reported net sales of US$494k and a net loss after income tax of US$22.9 million, with a loss per share of US$0.28.
Operating loss for the quarter widened to US$24.0 million, compared to US$21.8 million in the prior-year quarter.
Research and development expenses were substantial at US$17.5 million, reflecting the ongoing investment in the PARADIGM trial and product development.
Selling, general and administrative expenses amounted to US$6.9 million.
Related-party payments in Q1 2026 were US$2.3 million, included within operating cash flows.
Outlook and Risks
Anteris has made significant strides in advancing its PARADIGM trial with US enrolment and securing crucial funding.
However, sustained high cash burn for trial and manufacturing scale-up presents ongoing financing risk if patient recruitment does not meet expectations.
The ultimate success of the trial and regulatory approval remain key determinants for future commercialisation.
Get the wire before the market opens.
The ASX small-cap stories that matter, filed before 9am AEST. Curated by the Small Caps desk.